We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Priaxon Enters Collaboration with GSK on Protein-Protein-Interactions
News

Priaxon Enters Collaboration with GSK on Protein-Protein-Interactions

Priaxon Enters Collaboration with GSK on Protein-Protein-Interactions
News

Priaxon Enters Collaboration with GSK on Protein-Protein-Interactions

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Priaxon Enters Collaboration with GSK on Protein-Protein-Interactions"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Priaxon has announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions.

Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modulation of protein-protein interactions (PPIs).

PPIs play an important role in many cell signaling pathways and cell-surface receptor-ligand interactions that become dysregulated in disease states.

This collaboration will work to identify and advance candidates from hits to leads for pre-clinical development, with the long term interest of developing and commercializing drug candidates.

The agreement has been signed following a successful pilot project. Financial details as well as therapeutic fields of the collaboration are not disclosed.

"Using the strength of its unique drug discovery platform Priaxplore®, Priaxon will develop new small molecule modulators for hard-to-drug PPI targets," said Dr. Juergen Kolb, CEO of Priaxon.

Dr. Kolb continued, "Our collaboration with GSK and its experts provides the resources and the capabilities to drive these programs forward. We are looking forward to working together with the goal to develop small molecule modulators for various protein-protein interaction of high potential."

Advertisement